{"schema_version":"secwatch.filing_event.v1","accession":"0001576885-24-000015","form_type":"8-K","ticker":"ABOS","cik":"0001576885","company_name":"Acumen Pharmaceuticals, Inc.","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.676550+00:00","generated_at":"2026-06-07T02:17:02.214272+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"medium","headline":"Acumen posts updated corporate presentation with additional ACU193 biomarker data at J.P. Morgan Healthcare Conference","bullets":["Company posted updated corporate presentation on its website with additional biomarker data for ACU193.","Presentation used at J.P. Morgan Healthcare Conference on January 8, 2024.","No specific financial results or guidance changes disclosed.","ACU193 is an investigational drug for Alzheimer's disease."],"urls":{"canonical":"https://secwatch.observer/filing/0001576885-24-000015","json":"https://secwatch.observer/filing/0001576885-24-000015.json","markdown":"https://secwatch.observer/filing/0001576885-24-000015.md","text":"https://secwatch.observer/filing/0001576885-24-000015.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1576885/000157688524000015/0001576885-24-000015-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1576885/000157688524000015/abos-20240108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:17:02.214272+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}